

Figure S1. Predicted ligand docking positions on LRR receptor-like serine/threonine-protein kinase FEI 1 (LRR-FEI1) protein. (A) Predicted docking site highlighted in green mesh surface. (B) 5-MT ligand binding position (yellow) in comparison to template ligand (blue). (C) AAO ligand binding position (yellow) in comparison to template ligand. 5-MT: 5-methoxytryptamine; AAO: aminooxyacetic acid




Figure S2. Molecular interaction among 5-MT and AAO ligand on protein LRR-FEI1. (A) 3D interaction diagram between 5-MT (yellow) and LRR-FEI1 residue. (B) 2D diagram interaction between 5-MT and LRR-FEI1. (C) 3D interaction diagram between AAO (yellow) and LRR-FEI1. (D) 2D diagram interaction between AAO and LRR-FEI1. 5-MT: 5-methoxytryptamine; AAO: aminooxyacetic acid




Figure S3. Putative interaction between 5-MT ligand and protein 'probable inactive receptor kinase At5g58300' (At5g58300). (A) Predicted ligand docking site highlighted in green mesh surface. (B) 5-MT ligand binding position (yellow) in comparison to template ligand (blue). (C) 3D interaction diagram between 5-MT (yellow) and At5g58300. (D) 2D interaction diagram between 5-MT and At5g58300. 5-MT: 5-methoxytryptamine.






Figure S4. Putative interaction between 5-MT ligand and protein 'probable inactive receptor kinase At2g26730' (At2g26730). (A) Predicted ligand docking site highlighted in green mesh surface. (B) 5-MT ligand binding position (yellow) in comparison to template ligand (blue). (C) 3D interaction diagram between 5-MT (yellow) and At2g26730. (D) 2D interaction diagram between 5-MT and At2g26730. 5-MT: 5-methoxytryptamine